Persistent or severe symptoms especially severe abdominal pain, repeated vomiting, dehydration, or allergic symptoms warrant prompt medical evaluation
Molnupiravir and risk of post-acute sequelae of Covid-19: cohort study
Current formulations of GLP-1 analogs rely primarily on subcutaneous injections, which may pose challenges to patient convenience and long-term adherence
In most cases, this type of hair loss is temporary and treatable
Contrave highlights of prescribing information, Food and Drug Administration (2024) Wegovy highlights of prescribing information, Food and Drug Administration (2024) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2010) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Label: Contrave extended-release naltrexone hydrochloride and bupropion hydrochloride tablet, extended release, DailyMed (2024) Label: Wegovy- semaglutide injection, solution, DailyMed (2024) Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for Type 2 diabetes and obesity, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist that is legally available only to participants in Lilly clinical trials
